Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 10/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497183 | 0.76 | ABL1 (0.50) | ABL1NOS3NOS1NOS2FEN1 | |
| SCHEMBL4513696 | 0.74 | FEN1 (0.65) | FEN1ALOX5APKLKB1 | |
| SCHEMBL21020907 | 0.74 | PLA2G7 (0.47) | ABL1MAPK14DPP4ALDH1A1 | |
| SCHEMBL31512014 | 0.74 | NOS3 (0.50) | ABL1NOS3NOS1NOS2FEN1 | |
| SCHEMBL25294409 | 0.73 | UHRF1 (0.40) | NOS3NOS1NOS2FEN1ALOX5AP | |
| SCHEMBL21857575 | 0.72 | PDE3B (0.49) | MAPK14 | |
| Hydrochloric Acid SCHEMBL31512080 | 0.72 | NOS3 (0.48) | ABL1NOS3NOS1NOS2FEN1 | |
| SCHEMBL17813814 | 0.72 | POLQ (0.40) | ABL1MAPK14DPP4 | |
| SCHEMBL6642787 | 0.72 | KIT (0.43) | ABL1FEN1ALOX5APMAPK14DPP4 | |
| SCHEMBL11711471 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | ABL1 3675/4885NOS3 486/4885NOS1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.